Clinical Trial Update: A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing subcutaneous pembrolizumab coformulated with berahyaluronidase alfa (MK-3475A) to intravenous pembrolizumab in adults with metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Berahyaluronidase alfa (MK-3475A) (berahyaluronidase alfa)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic Non-small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-11-12